HPGC(SH:600664) Zheng Quan Zhi Xing·2025-09-03 16:08Core Viewpoint - The announcement details the pledge and unpledge of shares by the controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., indicating a significant portion of shares are pledged, which may impact the company's financial strategies and investor perceptions [1][2][3]. Summary by Sections Share Pledge and Unpledge Situation - Harbin Pharmaceutical Group holds 1,173,237,023 shares of the company, accounting for 46.58% of the total share capital. After the recent unpledge and repledge, a total of 926,857,248 shares are pledged, representing 79.00% of the shares held by Harbin Pharmaceutical Group and 36.80% of the company's total share capital [1][2]. - The recent unpledged shares amount to 148,571,428, which is 12.66% of the shares held by Harbin Pharmaceutical Group and 5.90% of the company's total share capital [1][2]. Future Pledge Situation - In the next six months, 688,021,638 shares will mature, which is 58.64% of the shares held by Harbin Pharmaceutical Group and 27.32% of the company's total share capital, with a corresponding financing balance of $80 million [3]. - There are no shares maturing within the next year, excluding those maturing in the next six months [3]. Financial Health and Impact on Company - Harbin Pharmaceutical Group's financial condition is reported to be good, with the ability to repay the pledged funds expected to come from self-generated and raised funds, indicating manageable pledge risks [3]. - The pledge situation is not expected to affect the company's actual control, daily management, or operational independence [3].